A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT00738530
- Phase
- PHASE3
- Status
- Completed
Conditions
- Renal Cell Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bevacizumab [Avastin] — DRUG10 mg/kg IV every 2 weeks
- Interferon alfa 2a [Roferon] — DRUG9 MIU SC 3 times/week
- Placebo — DRUGIV every 2 weeks
Study Details
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is greater than (\>)500 individuals.
Key Dates
- First listed
- Aug 20, 2008
- Start date
- Jun 30, 2004
- Status verified
- May 2016
- Primary completion
- Sep 30, 2008
- Completion
- Sep 30, 2008
Study Design
- Enrollment
- 649 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Bevacizumab + IFN-Alfa-2ABevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
- Placebo Comparator: Placebo + IFN-Alfa-2APlacebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
Primary Outcome Measure
Percentage of Participants Who Died [ Time Frame: Baseline up to 4.25 years ]
Related Studies
- Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing CancersPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid TumorsPHASE1/PHASE2 · Recruiting · Portage Biotech · Los Angeles, California
- A Study of IBI363 in Subjects with Advanced Solid MalignanciesPHASE2 · Recruiting · Innovent Biologics (Suzhou) Co. Ltd. · San Francisco, California
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyPHASE1/PHASE2 · Recruiting · 7 Hills Pharma, LLC · Aurora, Colorado